GB:0GHZ Stock Latest News
Company AnnouncementsXspray Pharma Targets Q4 2026 FDA Resubmissions for Dasynoc and Nilopki1M ago
Company AnnouncementsXspray Pharma Highlights CML Data Differentiating Dasynoc and Nilopki1M ago
Company AnnouncementsXspray Pharma to Showcase Commercial Oncology Strategy at Gothenburg Investor Update1M ago- Company AnnouncementsXspray Pharma to Hold Investor Update Alongside Key Leukemia Conference1M ago
Company AnnouncementsXspray Pharma Schedules Call After FDA Response on Lead Cancer Drug Dasynoc2M ago
Company AnnouncementsXspray Pharma Gets FDA Complete Response Letter on Dasynoc, Speeds Manufacturing for 2026 Resubmission2M agoCompany AnnouncementsXspray Pharma Bolsters Finances as FDA Decisions Loom for Nilopki and Dasynoc3M ago
Company AnnouncementsXspray Pharma Advances FDA Reviews for Nilopki and Dasynoc Amid Manufacturing Checks4M ago
Company AnnouncementsXspray Pharma Schedules Investor Call After FDA Letter on Nilopki5M ago
Company AnnouncementsXspray Pharma Hit by FDA Setback on Nilopki but Keeps HyNap Strategy on Track5M ago
Company AnnouncementsXspray Pharma Staff Fully Take Up Warrants as Key U.S. Oncology Launches Near5M ago
Company AnnouncementsXspray Pharma AGM Approves Incentive Programs and New Share Issue Mandate5M ago
Company AnnouncementsXspray Pharma Boosts Share Capital After Oversubscribed Rights Issue6M agoCompany AnnouncementsXspray Pharma Secures Funding and FDA Momentum as Losses Narrow in Q1 20266M ago
Company AnnouncementsXspray Pharma Raises SEK 113 Million in Oversubscribed Rights and Over-Allotment Issues6M ago
Company AnnouncementsXspray Wins FDA Nod on Nilopki Name, Sets Stage for Dual CML Drug Launch in U.S.6M ago
Company AnnouncementsXspray Pharma convenes 2026 AGM, sets voting rules and agenda6M ago- Company AnnouncementsXspray Pharma launches SEK 83m rights issue to fund oncology pipeline7M ago
- Company AnnouncementsXspray Pharma’s Rights Issue Oversubscribed and Over-Allotment Expanded7M ago
Company AnnouncementsXspray Pharma Publishes Comprehensive Annual Report for 20257M agoCompany AnnouncementsXspray Pharma Launches SEK 83 Million Rights Issue to Fund Oncology Drug Launches7M ago
Company AnnouncementsXspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch7M ago